GlaxoSmithKline PLC — Regulatory Filings 2021

Jan 20, 2021

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2021

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc (the ' Company ')

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms E Walmsley | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Executive Officer | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 920 |
| | | £13.9340 | 924 |
| | | £13.9340 | 740 |
| d) | Aggregated
information | 2,584 | |
| | Aggregated
volume Price | £13.9340 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Dr H Barron | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Scientific Officer and President, R&D | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 14 January 2021 on ADSs held
in the Company's Deferred Annual Bonus Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $38.1600 | 539 |
| | | $38.1600 | 423 |
| d) | Aggregated
information | 962 | |
| | Aggregated
volume Price | $38.1600 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | New York Stock Exchange (XNYS) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr R Connor | |
| --- | --- | --- | --- |
| b) | Position/status | President, Global Vaccines | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 195 |
| | | £13.9340 | 241 |
| | | £13.9340 | 233 |
| d) | Aggregated
information | 669 | |
| | Aggregated
volume Price | £13.9340 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms D Conrad | |
| --- | --- | --- | --- |
| b) | Position/status | SVP Human Resources | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 96 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr J Ford | |
| --- | --- | --- | --- |
| b) | Position/status | Senior Vice President and General Counsel | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 137 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr J Ford | |
| --- | --- | --- | --- |
| b) | Position/status | Senior Vice President and General Counsel | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 14 January 2021 on ADSs held
in the Company's Deferred Annual Bonus Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $38.1600 | 46 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | New York Stock Exchange (XNYS) | |

| 1. | Details of PDMR/person closely associated with them
('PCA') | |
| --- | --- | --- |
| a) | Name | Mr N Hirons |
| b) | Position/status | SVP, Global Ethics & Compliance |
| c) | Initial
notification/amendment | Initial
notification |

| 2. — a) | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor — Name | GlaxoSmithKline plc | |
| --- | --- | --- | --- |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 102 |
| | | £13.9340 | 72 |
| | | £13.9340 | 101 |
| d) | Aggregated
information | 275 | |
| | Aggregated
volume Price | £13.9340 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms S Jackson | |
| --- | --- | --- | --- |
| b) | Position/status | SVP, Global Communications & CEO Office | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 58 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr I Mackay | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Financial Officer | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 499 |
| d) | Aggregated
information | N/A (single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr B McNamara | |
| --- | --- | --- | --- |
| b) | Position/status | CEO, GSK Consumer Healthcare | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 14 January 2021 on ADSs held
in the Company's Deferred Annual Bonus Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $38.1600 | 90 |
| | | $38.1600 | 96 |
| | | $38.1600 | 78 |
| d) | Aggregated
information | 264 | |
| | Aggregated
volume Price | $38.1600 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | New York Stock Exchange (XNYS) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr L Miels | |
| --- | --- | --- | --- |
| b) | Position/status | President, Global Pharmaceuticals | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 185 |
| | | £13.9340 | 224 |
| | | £13.9340 | 256 |
| d) | Aggregated
information | 665 | |
| | Aggregated
volume Price | £13.9340 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr D Redfern | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Strategy Officer | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 190 |
| | | £13.9340 | 228 |
| | | £13.9340 | 164 |
| d) | Aggregated
information | 582 | |
| | Aggregated
volume Price | £13.9340 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr R Simard | |
| --- | --- | --- | --- |
| b) | Position/status | President, Pharmaceuticals Supply Chain | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 82 |
| | | £13.9340 | 116 |
| d) | Aggregated
information | 198 | |
| | Aggregated
volume Price | £13.9340 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Ms K Terrell | |
| --- | --- | --- | --- |
| b) | Position/status | Chief Digital & Technology Officer | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | |
| b) | Nature
of the transaction | Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 14 January 2021 on ADSs held
in the Company's Deferred Annual Bonus Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | $38.1600 | 32 |
| | | $38.1600 | 114 |
| | | $38.1600 | 79 |
| d) | Aggregated
information | 225 | |
| | Aggregated
volume Price | $38.1600 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | New York Stock Exchange (XNYS) | |

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr P Thomson | |
| --- | --- | --- | --- |
| b) | Position/status | President, Global Affairs | |
| c) | Initial
notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature
of the transaction | Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 14 January 2021
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £13.9340 | 128 |
| | | £13.9340 | 133 |
| | | £13.9340 | 94 |
| d) | Aggregated
information | 355 | |
| | Aggregated
volume Price | £13.9340 | |
| e) | Date
of the transaction | 2021-01-18 | |
| f) | Place
of the transaction | London Stock Exchange (XLON) | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: January
20, 2021
By:/s/ VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break